Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated December 01, 2025, titled "Sun Pharma introduces its global innovative drug, Ilumya® inIndia for treatment of moderate-to-severe Plaque Psoriasis".
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sun Pharma has launched its global innovative drug Ilumya® in India for the treatment of moderate-to-severe Plaque Psoriasis. The launch is backed by a press release dated December 01, 2025. Ilumya® is already sold in global markets and is now being introduced to the Indian market, expanding the company's dermatology portfolio. This marks a significant addition to Sun Pharma's specialty/branded prescription business in India.
Positive for Sun Pharma — adds a premium specialty drug to its India portfolio, potentially boosting domestic specialty revenues, though the overall financial impact will depend on adoption rates and pricing. Likely viewed favorably by the market as it leverages a globally validated product.